1.
|
12 p, 608.0 KB |
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk
/
Gatell, José Mª (Hospital Clínic i Provincial de Barcelona) ;
Assoumou, Lambert (UPMC Univ Paris 06) ;
Moyle, Graeme (St Chelsea and Westminster Hospital) ;
Waters, Laura (Mortimer Market Center) ;
Johnson, Margaret (Royal Free Hospital) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Fox, Julie (Guys and St. Thomas Hospital) ;
Martinez, Esteban (Hospital Clínic i Provincial de Barcelona) ;
Stellbrink, Hans-Jürgen (ICH Study Centrum) ;
Guaraldi, Giovanni (University of Modena and Reggio Emilia) ;
Masia, Mar (Hospital General Universitario de Elche) ;
Gompels, Marl (Southmead Hospital) ;
De Wit, Stephane (Université Libre de Bruxelles) ;
Florence, Eric (Institute of Tropical Medicine) ;
Esser, Stefan (Universitatsklinikum) ;
Raffi, François (CHU de Nantes) ;
Pozniak, Anton L. (St Chelsea and Westminster Hospital) ;
Universitat Autònoma de Barcelona
To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen. HIV type 1-infected adults more than 50 years or with a Framingham score more than 10% were eligible if plasma HIV RNA less than 50 copies per ml for at least 24 weeks while on a PI/r regimen. [...]
2017 - 10.1097/QAD.0000000000001675
AIDS, Vol. 31 Núm. 18 (28 2017) , p. 2503-2514
|
|
2.
|
11 p, 844.7 KB |
Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals
/
Kawana-Tachikawa, Ai (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Llibre, Josep M. (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ;
Bravo, Isabel (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ;
Escrig, Roser (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ;
Mothe, Beatriz (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ;
Puig, Jordi (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ;
Puertas, Maria C. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Martinez-Picado, Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Blanco, Julià (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Manzardo, Christian (Hospital Clínic i Provincial de Barcelona) ;
Miro, Jose M. (Hospital Clínic i Provincial de Barcelona) ;
Iwamoto, Aikichi (The Institute of Medical Science, The University of Tokyo, Japan) ;
Pozniak, Anton L. (HIV/GUM Department, Chelsea and Westminster Hospital, London, United Kingdom) ;
Gatell, Jose M. (Hospital Clínic i Provincial de Barcelona) ;
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ;
Brander, Christian (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. [...]
2014 - 10.1371/journal.pone.0087334
PloS one, Vol. 9 (january 2014)
|
|
3.
|
19 p, 1.1 MB |
Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort
/
Garriga, César (Instituto de Salud Carlos III) ;
García de Olalla, Patricia (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Miró, Josep M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ocaña Rivera, Immaculada (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Knobel Freud, Hernando (Hospital del Mar (Barcelona, Catalunya)) ;
Barberà, Maria Jesús (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Humet, Victoria (Generalitat de Catalunya. Direcció General de Serveis Penitenciaris i de Rehabilitació) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Gatell, Josep M.. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ribera, Esteve (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gurguí, Mercè (Institut d'Investigació Biomèdica Sant Pau) ;
Marco, Andrés (Generalitat de Catalunya. Direcció General de Serveis Penitenciaris i de Rehabilitació) ;
Caylà, Joan A.. (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública)
Antiretroviral therapy has led to a decrease in HIV-related mortality and to the emergence of non-AIDS defining diseases as competing causes of death. This study estimates the HIV mortality rate and their risk factors with regard to different causes in a large city from January 2001 to June 2013. [...]
2015 - 10.1371/journal.pone.0145701
PloS one, Vol. 10 (december 2015)
|
|
4.
|
13 p, 274.5 KB |
HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels
/
López-Dupla, Miguel (Hospital Universitari Joan XXIII de Tarragona) ;
Maymó-Masip, Elsa (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Martínez, Esteban (Hospital Clínic i Provincial de Barcelona) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Leal, Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Peraire, Joaquim (Hospital Universitari Joan XXIII de Tarragona) ;
Viladés, Consuelo (Hospital Universitari Joan XXIII de Tarragona) ;
Veloso, Sergi (Hospital Universitari Joan XXIII de Tarragona) ;
Arnedo, Mireia (Hospital Clínic i Provincial de Barcelona) ;
Ferrando-Martínez, Sara (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Beltrán-Debón, Raúl (Hospital Universitari Joan XXIII de Tarragona. Institut d'Investigació Sanitària Pere Virgili) ;
Alba, Verónica (Hospital Universitari Joan XXIII de Tarragona. Institut d'Investigació Sanitària Pere Virgili) ;
Gatell, Josep Mª (Hospital Clínic i Provincial de Barcelona) ;
Vendrell, Joan (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Vidal, Francesc (Hospital Universitari Joan XXIII de Tarragona) ;
Chacón, Matilde R. (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Universitat Autònoma de Barcelona
Obesity and HIV-1/HAART-associated lipodystrophy syndrome (HALS) share clinical, pathological and mechanistic features. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional cytokine that plays an important role in obesity and related diseases. [...]
2015 - 10.1371/journal.pone.0144789
PloS one, Vol. 10 (december 2015)
|
|
5.
|
14 p, 1.0 MB |
Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration : Randomized crossover clinical trial in healthy volunteers
/
Barroso, Sergio (Universitat Autònoma de Barcelona) ;
Morén, Constanza (Universitat de Barcelona) ;
González-Segura, Àlex (Universitat de Barcelona) ;
Riba, Neus (Hospital Clínic i Provincial de Barcelona) ;
Arnaiz, Joan A. (Hospital Clínic i Provincial de Barcelona) ;
Manriquez, Marcela (Hospital Clínic i Provincial de Barcelona) ;
Santana, Gemina (Hospital Clínic i Provincial de Barcelona) ;
Blanco, José L. (Hospital Clínic i Provincial de Barcelona) ;
Larousse, María (Hospital Clínic i Provincial de Barcelona) ;
Loncà, Montse (Hospital Clínic i Provincial de Barcelona) ;
de Lazzari, Elisa (Universitat de Barcelona) ;
Llopis, Jaume (Universitat de Barcelona) ;
Mallolas, Josep (Hospital Clínic i Provincial de Barcelona) ;
Miró, Oscar (Hospital Clínic i Provincial de Barcelona) ;
Carné, Xavier (Hospital Clínic i Provincial de Barcelona) ;
Gatell, José M. (Hospital Clínic i Provincial de Barcelona) ;
Garrabou, Glòria (Universitat de Barcelona) ;
Martínez, Esteban (Hospital Clínic i Provincial de Barcelona)
Context Classical antiretroviral agents may acutely impact on metabolic, mitochondrial, renal and hepatic function in HIV-infected and uninfected persons. Fusion and integrase inhibitors are supposed to be safer, but have been scarcely investigated. [...]
2019 - 10.1371/journal.pone.0216712
PloS one, Vol. 14 Núm. 5 (may 2019) , p. e0216712
|
|
6.
|
11 p, 1.6 MB |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
/
Eron, J. J. (University of North Carolina School of Medicine) ;
Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ;
Cunningham, D. (Pueblo Family Physicians) ;
Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Post, F. (King's College Hospital NHS Foundation Trust) ;
De Wit, Stéphane (Université Libre de Bruxelles) ;
Lathouwers, E. (Janssen Pharmaceutica NV) ;
Hufkens, V. (Janssen Pharmaceutica NV) ;
Jezorwski, J. (Janssen Research & Development) ;
Petrovic, R. (Janssen Pharmaceutica NV) ;
Brown, K. (Janssen Pharmaceutica NV) ;
Van Landuyt, E. (Janssen Pharmaceutica NV) ;
Opsomer, M. (Janssen Pharmaceutica NV) ;
De Wit, Stéphane (Université Libre de Bruxelles) ;
Florence, E. (Institute of Tropical Medicine) ;
Moutschen, M. (Liège University Hospital (Bèlgica)) ;
Van Wijngaerden, E. (University Hospitals Leuven (Bèlgica)) ;
Vandekerckhove, L. (Ghent University Hospital. (Bèlgica)) ;
Vandercam, B. (AIDS Reference center. Cliniques Universitaires Saint-Luc) ;
Brunetta, J. (Maple Leaf Medical Clinic) ;
Conway, B. (Vancouver Infectious Diseases Center) ;
Klein, M. (Division of Infectious Diseases. Faculty of Medicine. McGill University Health Centre) ;
Murphy, D. (Institut national de santé publique du Québec) ;
Rachlis, A. (Sunnybrook Health Sciences Centre) ;
Shafran, S. (Department of Medicine. University of Alberta) ;
Walmsley, S. (University Health Network) ;
Ajana, F. (Infectious Diseases Department. Tourcoing Hospital) ;
Cotte, L. (Hospices Civils de Lyon. Hôpital de la Croix-Rousse) ;
Girardy, P. M. (University Pierre & Marie Curie) ;
Katlama, C. (HIV Clinical Research Unit) ;
Molina, J. M. (Department of Infectious Diseases. St-Louis Hospital APHP. University of Paris Diderot) ;
Poizot-Martin, I. (Clinical Immuno-Hematology Department. Aix-Marseille University. Sainte-Marguerite University Hospital and Inserm U912) ;
Raffi, F. (CHU Hôtel Dieu) ;
Rey, D. (Le Trait d'Union. HIV-Infection Care Center. Hôpitaux Universitaires de Strasbourg) ;
Reynes, J. (University Hospital of Montpellier (França)) ;
Teicher, E. (Infectious Diseases Department. APHP. Hôpital Bicêtre) ;
Yazdanpanah, Y. ;
Gasiorowski, J. (Independent Laboratory for Monitoring Infections among Drug Users at the Department of Infectious Diseases. Liver Disease and Acquired Immune Deficiencies. Wroclaw Medical University) ;
Halota, W. (Department of Infectious Diseases and Hepatology. Nicolaus Copernicus University) ;
Horban, A. (Medical University of Warsaw. Department for Adult's Infectious Diseases) ;
Piekarska, A. (Department of Infectious Diseases and Hepatology. Medical University of Lodz) ;
Witor, A. (Regional Hospital. Out-Patient's Clinic for Immune Deficiency) ;
Arribas, J. R. (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Perez-Valero, I. (Hospital Universitario La Paz (Madrid)) ;
Berenguer, Juan (Hospital General Universitario Gregorio Marañón) ;
Casado, José A. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Gatell, J. M. (Infectious Diseases Department. HCB) ;
Gutiérrez, Félix (Hospital General Universitario de Elche) ;
Galindo, María José (Hospital Clínic Universitari (València)) ;
Gutiérrez Macià, Mª Del Mar (Institut d'Investigació Biomèdica Sant Pau) ;
Iribarren, J. A. (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Knobel Freud, Hernando (Hospital del Mar (Barcelona, Catalunya)) ;
Negredo Puigmal, Eugènia. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Pineda, J. A. (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ;
Podzamczer, Daniel (Institut d'Investigació Biomèdica de Bellvitge) ;
Sogorb, J. P. (Hospital Universitario 12 de Octubre (Madrid)) ;
Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Ricart, C. (Department of Microbiology. School of Medicine. University of Valencia) ;
Rivero, Antonio (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Santos Gil, I. (Hospital Universitario de la Princesa (Madrid)) ;
Blaxhult, A. (Department of Infectious Diseases. Venhälsan. Södersjukhuset) ;
Flamholc, L. (Skåne University Hospital (Suècia)) ;
Gisslèn, M. (Department of Infectious Diseases. University of Gothenburg) ;
Thalme, A. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Fehr, J. (University Hospital Zurich (Suïssa)) ;
Rauch, A. (Bern University Hospital) ;
Stoeckle, M. (University Hospital Basel (Basilea, Suïssa)) ;
Clarke, A. (Claude Nicol Centre. Royal Sussex County Hospital. Brighton and Sussex University Hospitals NHS Trust) ;
Gazzard, B. G. (St. Stephen's Centre. Department of HIV/Genito-Urinary Medicine. Chelsea and Westminster Hospital) ;
Johnson, M. A. (Queen Mary University) ;
Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ;
Post, F. (King's College Hospital NHS Foundation Trust) ;
Ustianowski, Andrew (Regional Infectious Diseases Unit. North Manchester General Hospital) ;
Waters, L. (University College London Hospital) ;
Bailey, J. (Department of Medicine. Johns Hopkins University School of Medicine) ;
Benson, P. (Be Well Medical) ;
Bhatti, L. (AIDS Healthcare Foundation) ;
Brar, I. (Henry Ford Hospital) ;
Bredeek, U. F. (Metropolis Medical PC) ;
Brinson, C. (Central Texas Clinical Research) ;
Crofoot, G. (The Crofoot Research Center) ;
Cunningham, D. (Pueblo Family Physicians) ;
DeJesus, E. (Pueblo Family Physicians) ;
Dietz, C. (Orlando Immunology Center) ;
Dretler, R. (HIV Medicine. Kansas City Free Health Clinic) ;
Eron, J. (Infectious Disease Specialists of Atlanta) ;
Felizarta, F. (Private Practice) ;
Fichtenbaum, C. (University of Cincinnati College of Medicine) ;
Gallant, J. (Southwest CARE Center) ;
Gathe, J. (Therapeutic Concepts) ;
Hagins, D. (Georgia Department of Public Health. Chatham Care Center) ;
Henn, S. (Whitman-Walker Health) ;
Henry, W. K. (Department of Medicine. University of Minnesota Washington University School of Medicine) ;
Huhn, G. (Ruth M. Rothstein CORE Center) ;
Jain, M. (Department of Internal Medicine. University of Texas Southwestern Medical Center) ;
Lucasti, C. (South Jersey Infectious Disease) ;
Martorell, C. (Infectious Disease and The Research Institute) ;
McDonald, C. (Tarrant County Infectious Disease Associates) ;
Mills, A. (Southern California Men's Medical Group) ;
Morales-Ramirez, J. (Clinical Research Puerto Rico Inc.) ;
Mounzer, K. (Philadelphia FIGHT) ;
Nahass, R. (ID Care) ;
Olivet, H. (Community Research Initiative of New England) ;
Osiyemi, O. (Triple O Research Institute PA) ;
Prelutsky, D. (Department of Internal Medicine. Washington University School of Medicine) ;
Ramgopal, M. (Midway Immunology Center. Fort Pierce) ;
Rashbaum, B. (Capital Medical Associates) ;
Richmond, G. (Broward General Medical Center) ;
Ruane, P. (Ruane Clinical Research Group) ;
Scarsella, A. (Pacific Oaks Medical Group) ;
Scribner, A. (DCOL Center for Clinical Research) ;
Shalit, P. (Peter Shalit MD and Associates) ;
Shamblaw, D. (La Playa Medical Group) ;
Slim, J. (Department of Infectious Diseases. Seton Hall University) ;
Tashima, K. (The Miriam Hospital. Warren Alpert Medical School of Brown University) ;
Voskuhl, G. (AIDS Arms. Inc.) ;
Ward, D. (Dupont Circle Physicians Group) ;
Wilkin, A. (Wake Forest School of Medicine) ;
de Vente, J. (Living Hope Foundation) ;
Universitat Autònoma de Barcelona
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. [...]
2019 - 10.1016/j.antiviral.2019.104543
Antiviral Research, Vol. 170 (october 2019) , p. 104543
|
|
7.
|
10 p, 763.1 KB |
Engineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG
/
Saubi, Narcis (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gea-Mallorquí, Ester (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ferrer, Pau (Universitat Autònoma de Barcelona. Departament d'Enginyeria Química, Biològica i Ambiental) ;
Hurtado, Carmen (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Sánchez-Úbeda, Sara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Eto, Yoshiki (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gatell, Josep M.. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Hanke, Tomáš (University of Oxford. Weatherall Institute of Molecular Medicine) ;
Joseph, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
In this study, we have engineered a new mycobacterial vaccine design by using an antibiotic-free plasmid selection system. We assembled a novel Escherichia coli (E. coli)-mycobacterial shuttle plasmid p2auxo. [...]
2014 - 10.1038/mtm.2014.17
Molecular Therapy. Methods & Clinical Development, Vol. 1 (May 2014) , art. 14017
|
|
8.
|
20 p, 1.4 MB |
A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART
/
Gómez, Carmen Elena (Centro Nacional de Biotecnología (Madrid, Espanya)) ;
Perdiguero, Beatriz (Centro Nacional de Biotecnología (Madrid, Espanya)) ;
García-Arriaza, Juan (Centro Nacional de Biotecnología (Madrid, Espanya)) ;
Cepeda, Victoria (Centro Nacional de Biotecnología (Madrid, Espanya)) ;
Sánchez-Sorzano, Carlos Óscar (Centro Nacional de Biotecnología (Madrid, Espanya)) ;
Mothe, Beatriz (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Jiménez, José Luis (Hospital General Universitario Gregorio Marañón) ;
Muñoz-Fernández, María Ángeles (Hospital General Universitario Gregorio Marañón) ;
Gatell, José María (Hospital Clínic i Provincial de Barcelona) ;
López Bernaldo de Quirós, Juan Carlos (Hospital General Universitario Gregorio Marañón) ;
Brander, Christian (Institució Catalana de Recerca i Estudis Avançats) ;
García, Felipe (Hospital Clínic i Provincial de Barcelona) ;
Esteban, Mariano (Centro Nacional de Biotecnología (Madrid, Espanya)) ;
Universitat Autònoma de Barcelona
TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. [...]
2015 - 10.1371/journal.pone.0141456
PloS one, Vol. 10 Núm. 11 (november 2015)
|
|